Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain

Pain Practice : the Official Journal of World Institute of Pain
Egilius L H SpieringsRicardo Vallejo

Abstract

Chronic opioid analgesic use often causes opioid-induced constipation (OIC). This open-label extension study evaluated the safety and efficacy of lubiprostone, a chloride channel (ClC-2) activator, for treatment of OIC in patients with chronic noncancer pain. Adults with OIC were enrolled from two 12-week, placebo-controlled, double-blind studies and received lubiprostone 24 μg twice daily for up to 9 months. OIC was defined as < 3 spontaneous bowel movements (SBMs)/week during the 2-week baseline period, of which ≥ 25% were characterized by hard to very hard stool consistency, subjectively incomplete evacuation, and/or moderate or worse straining. Inclusion criteria required consistent treatment with full opioid agonists ≥ 30 days prior to screening and throughout the study. All 439 patients who received lubiprostone were analyzed for safety and efficacy. Overall, 24.6% of patients reported treatment-related adverse events (AEs), most commonly nausea (5.0%), diarrhea (4.6%), headache (1.6%), and vomiting (1.4%). No treatment-related serious AEs were reported. Nausea and diarrhea each led to study discontinuation in 5 patients (1.1%); 2 cases each of nausea and diarrhea were rated as severe. Rescue medication usage decreased fr...Continue Reading

References

Jun 24, 2004·American Journal of Physiology. Cell Physiology·John CuppolettiRyuji Ueno
Sep 11, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·J D Wood, J J Galligan
Aug 13, 2005·European Journal of Pain : EJP·Harald BreivikDerek Gallacher
Apr 7, 2007·Journal of Clinical Gastroenterology·Brian E Lacy, L Campbell Levy
May 24, 2007·The Annals of Pharmacotherapy·Emily M Ambizas, Regina Ginzburg
Aug 30, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Timothy J BellRussell Williamson
Apr 7, 2009·Regulatory Peptides·Peter Holzer
Sep 1, 2009·Pharmacoepidemiology and Drug Safety·Denise BoudreauConstance Weisner
Nov 21, 2009·Current Opinion in Gastroenterology·Jackie D Wood
Jan 27, 2010·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·A K TutejaA G Lipman
Aug 28, 2010·The Journal of Pain : Official Journal of the American Pain Society·Catherine B JohannesRobert H Dworkin
Dec 25, 2010·Digestive Diseases and Sciences·Xiaohong SunJackie D Wood
Mar 10, 2011·Expert Opinion on Pharmacotherapy·Banny S Wong, Michael Camilleri
Jan 24, 2012·Journal of Psychiatric Research·Maurice M Ohayon, Julia C Stingl
Apr 11, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Byron CryerRyuji Ueno
Dec 5, 2014·The Annals of Pharmacotherapy·James Leonard, Danial E Baker

❮ Previous
Next ❯

Citations

Oct 10, 2015·Current Oncology Reports·Mellar Davis, Pamela Gamier
Aug 6, 2016·Mayo Clinic Proceedings·Adil E BharuchaChristopher D Sletten
Nov 3, 2017·The Annals of Pharmacotherapy·Julie A Murphy, Erica A Sheridan
Aug 11, 2020·Expert Review of Gastroenterology & Hepatology·Marzieh DanialiMohammad Abdollahi
Jul 18, 2017·Frontiers in Pharmacology·Hong Yang, Tonghui Ma
Oct 6, 2018·United European Gastroenterology Journal·Jasper PannemansJan Tack
May 6, 2019·Mayo Clinic Proceedings·Adil E Bharucha, Arnold Wald
Oct 17, 2020·Oncology Nursing Forum·Barbara RogersRebecca L Morgan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.